Capricor Therapeutics - CAPR Stock Forecast, Price & News

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Capricor Therapeutics to a "sell" rating in a research note on Monday, May 23rd.

Capricor Therapeutics Stock Up 4.3 %

NASDAQ:CAPR opened at $5.10 on Wednesday. The company has a market cap of $124.05 million, a P/E ratio of -4.90 and a beta of 5.00. Capricor Therapeutics has a fifty-two week low of $2.56 and a fifty-two week high of $5.85. The firm's 50 day moving average is $4.35 and its two-hundred day moving average is $4.02.

Capricor Therapeutics (NASDAQ:CAPR - Get Rating) last issued its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same quarter last year, the firm earned ($0.21) EPS. Research analysts forecast that Capricor Therapeutics will post -1.17 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the transaction, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total value of $106,370.55. Following the transaction, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David B. Musket sold 17,775 shares of Capricor Therapeutics stock in a transaction on Monday, June 27th. The stock was sold at an average price of $4.44, for a total transaction of $78,921.00. Following the sale, the director now directly owns 40,962 shares in the company, valued at approximately $181,871.28. The disclosure for this sale can be found here. Insiders own 9.00% of the company's stock.